作者
Mark P van Opijnen, C Mircea S Tesileanu, Linda Dirven, Pim B van der Meer, Maarten MJ Wijnenga, Arnaud JPE Vincent, Marike LD Broekman, Hendrikus J Dubbink, Johan M Kros, Sjoerd G van Duinen, Marion Smits, Pim J French, Martin J van den Bent, Martin JB Taphoorn, Johan AF Koekkoek
发表日期
2023/4/1
期刊
Neuro-oncology
卷号
25
期号
4
页码范围
701-709
出版商
Oxford University Press
简介
Background
IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or + 7/−10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered glioblastoma IDHwt according to the WHO 2021 classification. However, differences in seizure onset have been observed. This study aimed to compare the course of epilepsy in the 2 glioblastoma subtypes.
Methods
We analyzed epilepsy data of an existing cohort including IDHwt histologically lower-grade glioma WHO grade 2 and 3 with molecular glioblastoma-like profile (IDHwt hLGG) and IDHwt glioblastoma patients. Primary outcome was the incidence proportion of epilepsy during the disease course. Secondary outcomes included, among others, onset of epilepsy, number of seizure days, and antiepileptic drug …
学术搜索中的文章
MP van Opijnen, CMS Tesileanu, L Dirven… - Neuro-oncology, 2023